Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Frontiers in Pharmacology

Chia-Hung Kao¹  Cheng-Li Lin²  Cheng-Chieh Lin³  Chun-Hao Tsai⁵  Shih-Yi Lin⁶  Wu-Huei Hsu⁷  Chung-Y. Hsu⁸  Hung-Chieh Yeh⁹ 

[1] 0Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan;Department of Nuclear Medicine, China Medical University Hospital, Taichung, Taiwan;Department of Orthopedics, China Medical University Hospital, Taichung, Taiwan;Division of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, Taiwan;Division of Pulmonary and Critical Care Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan;Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan;Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan;Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan;

关键词: fracture;    sitagliptin;    dipeptidyl peptidase-4 inhibitor;    cohort study;    diabetes;   

DOI  :  10.3389/fphar.2018.00677

来源: DOAJ

【 摘 要 】

Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.Methods: The sitagliptin cohort included 1,578 patients aged 20 years and above. The nonsitagliptin cohort comprised propensity-score matched patients at a ratio of 1:1. The primary outcome was the incidence of fractures, which was evaluated using Kaplan–Meier survival analysis and proportional hazards modeling.Results: The mean age of patients in the sitagliptin and nonsitagliptin cohorts was 63.1 and 63.3 years, respectively. The incidence of fractures in the sitagliptin cohort was 46 per 1,000 person-years and that in the nonsitagliptin cohort was 40.8 per 1,000 person-years. Compared with patients in the nonsitagliptin cohort, those in the sitagliptin cohort who received sitagliptin for ≥250 days had a higher risk of fracture (aHR = 1.32, 95% CI = 1.06–1.64).Conclusion: Using sitaglipin ≥250 days was associated with an increased risk of fracture.

【 授权许可】

Unknown